Safety and Efficacy of Radioembolization in Elderly (≥ 70 Years) and Younger Patients With Unresectable Liver-Dominant Colorectal Cancer.
Publication/Presentation Date
6-1-2016
Abstract
BACKGROUND: The effects of advancing age on clinical outcomes after radioembolization (RE) in patients with unresectable liver-dominant metastatic colorectal cancer (mCRC) are largely unknown.
PATIENTS AND METHODS: This study was a retrospective analysis of 160 elderly (≥ 70 years) and 446 younger (< 70 years) consecutive patients from 11 US centers who received RE using ytrrium-90 ((90)Y) resin microspheres ((90)Y radioembolization [(90)Y-RE]) between July 2002 and December 2011. A further analysis was conducted in 98 very elderly patients (≥ 75 years). Statistical analyses of safety, tolerability, and overall survival were conducted.
RESULTS: Mean ages (± standard deviation) in the younger (< 70 years), elderly (≥ 70 years), and very elderly (≥ 75 years) cohorts were 55.9 ± 9.4 years, 77.2 ± 4.8 years, and 80.2 ± 3.8 years, respectively. Overall survival was similar between elderly and younger patients: 9.3 months (95% confidence interval [CI], 8.0-12.1) and 9.7 months (95% CI, 9.0-11.4) (P = .335). There were no differences between cohorts for any grade adverse events (P = .433) or grade 3+ events (P = .482). Analysis of patients ≥ 75 years and < 75 years confirmed similar overall survival (median, 9.3 months vs. 9.6 months, respectively; P = .987) and grade 3+ events (P = .398) or any adverse event (P = .158) within 90 days of RE.
CONCLUSION: For patients with unresectable liver-dominant mCRC who meet eligibility criteria for RE, (90)Y-RE microspheres appear to be effective and well-tolerated, regardless of age. Criteria for selecting patients for RE should not include age for exclusion from this potentially beneficial intervention.
Volume
15
Issue
2
First Page
141
Last Page
151
ISSN
1938-0674
Published In/Presented At
Kennedy, A. S., Ball, D. S., Cohen, S. J., Cohn, M., Coldwell, D., Drooz, A., Ehrenwald, E., Kanani, S., Rose, S. C., Nutting, C. W., Moeslein, F. M., Savin, M. A., Schirm, S., Putnam, S. G., 3rd, Sharma, N. K., Wang, E. A., & Metastatic Colorectal Cancer Liver Metastases Outcomes After Radioembolization (MORE) Study Investigators (2016). Safety and Efficacy of Radioembolization in Elderly (≥ 70 Years) and Younger Patients With Unresectable Liver-Dominant Colorectal Cancer. Clinical colorectal cancer, 15(2), 141–151.e6. https://doi.org/10.1016/j.clcc.2015.09.001
Disciplines
Medicine and Health Sciences
PubMedID
26541321
Department(s)
Hematology-Medical Oncology Division
Document Type
Article